The wait is finally over for investors! Today, December 11, 2025, is the official Basis of Allotment date for the Corona Remedies IPO. After a strong response from QIBs and NIIs during the subscription period, all eyes are now on the allotment status and the surging Grey Market Premium (GMP).
In this detailed update, we cover the latest GMP as of today, step-by-step instructions to check your allotment status on Bigshare Services, and the calculated listing price based on current market trends.
🚀 Quick Status Check (Dec 11)
- Allotment Status: Expected Today
- Latest GMP: ₹291 per share (Up from ₹270)
- Listing Gain: ~27.40%
📊 Check Live GMP Dashboard
Corona Remedies IPO GMP Today (December 11, 2025)
The Grey Market sentiment has strengthened significantly today. Despite market volatility, Corona Remedies is commanding a premium of nearly ₹300.
| Metric | Value |
|---|---|
| GMP Today | ₹291 per share |
| IPO Price Band | ₹1,062 per share |
| Est. Listing Price | ₹1,353 (₹1,062 + ₹291) |
| Percentage Gain | 27.40% |
| Subject to Sauda (SS) | ₹3,100 per Retail Lot |
How to Check Corona Remedies IPO Allotment Status?
Since Bigshare Services is the official registrar for this issue, you must check your status on their portal. Follow these steps:
Method 1: Via Bigshare Services Website
- Go to the Bigshare IPO Allotment Page.
- Select any one of the servers (Server 1, 2, or 3).
- In the "Company Selection" dropdown, look for "Corona Remedies Limited". (Note: If the name is not there, the allotment is not yet live. Keep refreshing.)
- Select "PAN Number" as your selection type.
- Enter your PAN and the Captcha code.
- Click "Search." Your allotment details will be displayed on the screen.
Method 2: Via BSE Website
- Visit the BSE IPO Application Status page.
- Under "Issue Type," select Equity.
- Under "Issue Name," select Corona Remedies Limited.
- Enter your Application Number or PAN.
- Click "Search."
Subscription Analysis: Why the GMP is Rising
The GMP uptick to ₹291 is driven by the strong subscription numbers seen on the final day.
- QIB (Qualified Institutional Buyers): Subscribed heavily, signaling long-term confidence in the pharma sector.
- NII (HNI Category): Saw oversubscription of 60.90x, creating a "scarcity premium" in the grey market.
- Retail: Subscribed 10.30x, making allotment tough for small investors.
Financial Health Snapshot
Before the listing on December 15, let's recap the fundamentals that are driving this price.
| Financial Metric | FY 2025 Figure |
|---|---|
| Revenue | ₹1,196 Crores |
| Net Profit (PAT) | ₹149.43 Crores |
| EBITDA | ₹246 Crores |
| P/E Valuation | ~43x (Fairly Valued) |
Listing Strategy: Hold or Sell?
With a 27-30% listing gain likely, here is a strategy for different investors:
- For Listing Gain Players: If the stock lists above ₹1,350, it is a good opportunity to book partial profits. The grey market has priced in most of the upside.
- For Long-Term Investors: Corona Remedies operates in high-growth chronic therapy areas (Women's Health, Cardiac). If you get an allotment, holding for the medium term (6-12 months) could yield better returns as the company utilizes its cash flow for expansion.
Disclaimer: The GMP prices quoted here are based on market rumors and are for educational purposes only. We are not SEBI-registered advisors. Please consult your financial advisor before investing.
No comments: